Dual Blockade of TGF-β Receptor and Endothelin Receptor Synergistically Inhibits Angiotensin II-Induced Myofibroblast Differentiation: Role of ATR/G-Mediated TGF-β1 and ET-1 Signaling
Overview
Chemistry
Molecular Biology
Affiliations
Angiotensin II (Ang II) upregulates transforming growth factor-beta1 (TGF-β1) and endothelin-1 (ET-1) in various types of cells, and all of them act as profibrotic mediators. However, the signal transduction of angiotensin II receptor (ATR) for upregulation of TGF-β1 and ET-1, and their effectors that play an essential role in myofibroblast differentiation, are not fully understood. Therefore, we investigated the ATR networking with TGF-β1 and ET-1 and identified the signal transduction of these mediators by measuring the mRNA expression of alpha-smooth muscle actin (α-SMA) and collagen I using qRT-PCR. Myofibroblast phenotypes were monitored by α-SMA and stress fiber formation with fluorescence microscopy. Our findings suggested that Ang II induced collagen I and α-SMA synthesis and stress fiber formation through the ATR/G axis in adult human cardiac fibroblasts (HCFs). Following ATR stimulation, G protein, not G subunit, was required for upregulation of TGF-β1 and ET-1. Moreover, dual inhibition of TGF-β and ET-1 signaling completely inhibited Ang II-induced myofibroblast differentiation. The ATR/G cascade transduced signals to TGF-β1, which in turn upregulated ET-1 via the Smad- and ERK1/2-dependent pathways. ET-1 consecutively bound to and activated endothelin receptor type A (ETR), leading to increases in collagen I and α-SMA synthesis and stress fiber formation. Remarkably, dual blockade of TGF-β receptor and ETR exhibited the restorative effects to reverse the myofibroblast phenotype induced by Ang II. Collectively, TGF-β1 and ET-1 are major effectors of ATR/G cascade, and therefore, negative regulation of TGF-β and ET-1 signaling represents a targeted therapeutic strategy for the prevention and restoration of cardiac fibrosis.
Pathophysiology, molecular mechanisms, and genetics of atrial fibrillation.
Han P, Zhao X, Li X, Geng J, Ni S, Li Q Hum Cell. 2024; 38(1):14.
PMID: 39505800 DOI: 10.1007/s13577-024-01145-z.
Shibata N, Ohashi Y, Tsukada A, Iwase D, Aikawa J, Mukai M Medicina (Kaunas). 2024; 60(5).
PMID: 38792924 PMC: 11122993. DOI: 10.3390/medicina60050741.
New Therapeutics for Heart Failure: Focusing on cGMP Signaling.
Mangmool S, Duangrat R, Parichatikanond W, Kurose H Int J Mol Sci. 2023; 24(16).
PMID: 37629047 PMC: 10454066. DOI: 10.3390/ijms241612866.